2022
DOI: 10.53730/ijhs.v6ns3.6898
|View full text |Cite
|
Sign up to set email alerts
|

Developing new treatment modalities from poorly dissolvable antihypertensive

Abstract: Most antihypertensive drugs have impaired dissolution rate and result from poorly aqueous solubility, polymorphic modifications, structure-based H-bond donor or acceptor anamolies. These physical attributes would have detrimental effects and may cause an entity out of the race from efficacious candidates. Nevertheless, compliance with the dissolution rate must be fulfilled under the regulatory mandate and serve as an assessment tool for product performance. The present reviews the niche technologies like elect… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles